Embed Size (px)
Citation preview
BarcelonaThe BioRegion of Catalonia
An expanding life sciences and healthcare startup ecosystem, based on world-class science, in a great city.
Rapid investment growth in life sciences startups
2016-2020
x41/week
A new company is created every week
+€225MInvestment in life
sciences and healthcare startups in 2020
Source: Biocat.*Private investment = Venture Capital, Private Equity, Stock Market, Crowdequity.
Investment growthin the last 5 years
(over the previous period)
2011-20150
100
200
300
400
500
600
Private investment*
Grants
Digital Health: A rapidly emerging subsector
2019-2021YTD*
X7X6Digital Health
startups in the last 10 years
+€34MInvestment in Digital Health startups in 2020
Source: Biocat.*2021YTD = April, 2021.
Investment growthin the last 5 years
(2016-2020)
2016-20180
20
40
60
80
100
Total Funding
(2011-2020)
Source: Crunchbase, report based on Seed, Venture Series, Angel, Crowdequity and Private Equity funding only.
A greatinvestment opportunity
Total VC/PE investment ($M) in emerging life sciences and healthcare startups (2016-2020)
3.3x
But the growth has only started
RECENT FOREIGN INVESTORS
of all investment in VC/PE rounds include foreign firms
57% from Europe (excl. Spain)30% from North America9% from Asia4% Other
A highly internationalized investment ecosystem
foreign VC/PE firmsinvesting in Barcelona startups73
Cumulative number of foreign investorsin life sciences and healthcare startups
Source: Biocat.
62%0
10
20
30
40
50
60
2015 2020
70
Find all angel investors, venture capital and private equity firms at: http://www.catalanlifesciences.com/
€700m Raised by specialised firms in the BioRegion,available for co-investment in the life sciences and healthcare
Source: Biocat.
Barcelona, home to specialized investors
OPEN FUNDS
€5-15m invested
Source: Biocat. Investments between 2015 and 2020, both included.
A diverse life sciences and healthcare startuplandscape
Biotechnology€30-150m invested
€15-30m invested
€1-5m invested
€5-15m invested
Medical Technology€30-150m invested
€1-5m invested
€5-15m invested
Digital Health
€1-5m invested
€30-150m invested
€15-30m invested
+200active companies
A booming Digital Health ecosystem
x2(2014-2019)
Source: Biocat. Illustrative representation. Relevant companies may not have been detected. Please contact us if you would like your company registered at http://www.catalanlifesciences.com/.
Source: Barcelona & Catalonia Start-up Hub (ACCIO) and Dealroom
5th Amsterdam4th Stockholm3rd Barcelona2nd Berlin1st Paris
3rd
EU TECH HUBby funding rounds for startups(all tech sectors, 2016-2020)
+1,700 startups(all sectors) +500 in Biotech, Medtech and Digital Health
#4 Berlin
#1 London
#5 BARCELONA
#7 Paris
#8 Amsterdam
Barcelona,
5th most invested city in Digital Health in Europe amid pandemic (2020–April 2021)
Source: Crunchbase, report based on Angel, Seed and Venture Capital Series funding only.
#2 Stockholm
#3 Oxford
#6 Copenhagen
#9 Marseille
#10 Oulu
+ US$ 100 M
US$ 50-100 M
US$ 30-50 M
Source: Startup Heatmap Europe, 2021.
Madrid
BARCELONA
Lisbon
London
Dublin Amsterdam Berlin
ViennaMunichZurich
Paris
Milan
Barcelona,
2nd most EU attractive city for startup founders
Source: Global Cities Investment Monitor - FDi Markets Database, 2018 and FDi Markets Magazine, 2019.
in the world by number of
international investments in R&D4th
TOP REGIONFinancial Times’ Southern Europe’s
for foreign investment
An opportunity to invest in world-class life sciences research & startups
Source: Nature Index, 2020.
8th Lausanne7th Oxford
6th Munich5th Berlin
4th Cambridge
10th Madrid9th Barcelona
3rd Zürich2nd Londonc
SCIENCE CITIES IN EUROPE,Nature Index
40th in the world
1st Paris
11th Stockholm12th Copenhaguen
13th Vienna14th Heidelberg
15th Amsterdam
With leading research centers, companies, hospitals and universities, Catalonia produces high quality life sciences and healthcare research at a large volume
Source: Scopus (Elsevier), SCIMAGO, SIRIS Academic. [Population] BEL=11,6M SWE=10M AUT= 9M CAT=7,5M DNK=5,8M FIN=5,5M IRL=4,9M
Source: CORDIS, UNiCS (SIRIS Academic), Biocat.
Catalan institutions and companies are very competitive in attracting EU funding, which supports the best research and innovation in Europe.
[Population] BEL=11,6M SWE=10M AUT= 9M CAT=7,5M DNK=5,8M FIN=5,5M IRL=4,9M
In 2020, 71% of Spain’s new ERC Advanced Grants have come to Catalonia.
Catalonia hosts 113 ERC grantees in the life sciences and healthcare, one of the highest ratios in Europe.The European Research Council (ERC) provides Europe’s most prestigiousand well-funded research grants.
Catalan institutions run excellent translational research, advancing rapidly towards commercialisation 1st
3rd
2nd CATALONIA
4th
5th
6th
7th
BELGIUM
SWEDEN
FINLAND
IRELAND
AUSTRIA
DENMARK
ERC PoC grants in the life sciences and healthcare
TRANS-LATIONAL RESEARCH
PROOF OF CONCEPT
BUSINESSFORMATION
/ LICENSING
BUSINESSGROWTH
(26)
The ERC Proof of Concept provides funding to bring ideas with commercial potential to a pre-demonstration stage, de-risking new technologies to commercial partners and investors.
Source: CORDIS, SIRIS Academic.
(15)
(13)
(11)
(10)
(9)
(6)
+400
Source: Biocat.
Synthetic biology
3D&Bio Printing
RNA Therapies
Genomics
Immunotherapies
deep tech companies
Biotech
Talented founders, with extensive pharma, clinical and research expertise
Digital Therapeutics
Telehealth
Bioinformatics
Digital Health
Big Data & Analytics
IoT
AR/VR
Artificial Intelligence
Blockchain
CS*/ICT
Electronics
Photonics
Advanced Materials
Robotics
Nanotechnology
KETs**
*Computer Science **Key Enabling Technologies
Source: Biocat.
A dynamic product pipelineBioRegion companies have 41 drugs and therapies in clinical development, covering a wide range of therapeutic areas.
In a world-class environment for clinical research
Source: Clinicaltrials.gov, SIRIS Academic.
Top pharma companies developing clinical trials in Catalonia
Number of active clinical trials
#13 worldwide#7 in the EU
Barcelona Supercomputing Center Alba SynchrotronNational Center
for Genomic AnalysisFully-equipped science and
business parks
And the best supporting research infrastructures
The right time to invest
x4 VC/PE investment growthin the last 5 years(over the previous period)
World-class life sciences research and startups
A great investment opportunityin Barcelona life sciences and healthcare startups
Source: ACCIO. More information: http://catalonia.com/.content/documents/RDIncentives_tcm213-241073.pdf
Generous tax incentives
Up to
59%for R&D
expenses
CORPORATE TAX EXEMPTION
Bonuses of
40%for R&D staff
SOCIAL SECURITY
Up to
60%of licensing
income exempted
PATENT BOX
Flat rate at
24%during the first
6 years
PERSONAL INCOME TAX FOR NON-RESIDENTS
● Accelerated introduction to local business practices and regulations (tax, corporate, labor, immigration law)
● Company incorporation, permits and paperwork
● Financing and incentives
Contact point: [email protected]
Tailored support for foreign investors
● Site selection and temporary spaces
● Talent recruitment
● Reliable suppliers and business partners
● Networking
Investment support services:
Browse and explore investment opportunities
http://www.catalanlifesciences.com/
Catalan Life Sciences Database
LS&H multinationals - Innovation centers - Map of main actors
[Annexes]
Ecosystem overview
BiotechAbility PharmaMinoryx TherapeuticsOna TherapeuticsPeptomycPulmobiotics
MedtechAnaconda BiomedGlycardial DiagnosticsSTAT-DX
Digital HealthMediktorPsiousQMENTA
Selected case studies
A Europeanlife sciences and healthcare
business hub
Source: Biocat
Innovation centersrecently set up in Barcelona
Source: Biocat
(2018-20)
Map of main actorsA rich ecosystem,at a walking distance
Source: Biocat
FOUNDED: 2009
BiotechnologySECTOR:
OncologyEXPERTISE / SPECIALITY / FOCUS:
Clinical Phase IISTAGE:
Founders: Maribel Bergés Fraile (CEO)
Institutions: Autonomous University of Barcelona (UAB)
2010: Seed Round (€1.5m; Founders)
2012: pre-Series A (€1m; Inveready, Genoma España)
2019: Series A (€3.5m; Inveready, Everis)
2020: SME Instrument II (€2.5m; European Commission)European Investment Bank (€2.5m)
Developing advanced cancer therapies that are based upon autophagy, suitable as monotherapy or as first-line therapy.
1 worldwide patentINTELLECTUAL PROPERTY
FOUNDED: 2011
BiotechnologySECTOR:
Orphan CNS DiseasesEXPERTISE / SPECIALITY / FOCUS:
Clinical Phase IIISTAGE:
Founders: Joan Aymamí & Xavier Barril
Institutions: University of Barcelona (UB)Institute of Research and Advanced Studies (ICREA)
2013: Series A (€1.5m; Caixa Capital Risc, Inveready, Mineco, Acció)
2015: Series B (€20m; Ysios, Kurma partners, Roche Ventures, Chiesi Ventures, Indivest partners, Caixa Capital Risc, HealthEquity, Sanfilippo foundation)
2018: Series B II (€22m; Fund+, Federal holding and investment group, Société Régionale d’investissement, Sambrinvest)SME Instrument II (€3.1m, European Commission)
Developing new therapies with an unique mechanism of action for rare central nervous system diseases of genetic origin.
FOUNDED: 2019
BiotechnologySECTOR:
OncologyEXPERTISE / SPECIALITY / FOCUS:
Founders: Valerie Vanhooren (CEO) & Salvador Aznar (CSO)
Institutions: Institute for Research in Biomedicine (IRB) Institute of Research and Advanced Studies (ICREA)
PreclinicalSTAGE:
2019: Seed round (€1.5m; Asabys Partners )
2020: Serie A (€30m, Asabys Partners, Alta Life Sciences, Bpifrance Fund+, Ysios Capital)
Developing specialized therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism.
FOUNDED: 2014
BiotechnologySECTOR:
OncologyEXPERTISE / SPECIALITY / FOCUS:
PreclinicalSTAGE:
Founders: Laura Soucek (CEO) & Marie-Eve Beaulieu
Institutions: Vall d’Hebron Institute of Oncology (VHIO) Institute of Research and Advanced Studies (ICREA)
2016: Seed Round (€1m; HealthEquity) SME Instrument I (€50k; European Commission, )
2017: Series A (€4m; Alta LS, HealthEquity)
2019: SME Instrument II (€2.2m; European Commission)
2020: Looking for Series B to finish clinical phase I/II
Developing Omomyc, a new generation of cell penetrating peptides targeting the Myc oncoprotein against a wide range of tumors.
4 worldwide patentsINTELLECTUAL PROPERTY
FOUNDED: 2020
BiotechnologySECTOR:
Infectious DiseasesEXPERTISE / SPECIALITY / FOCUS:
PreclinicalSTAGE:
Founders: Maria Lluch (CSO) & Luis Serrano (Advisor)
Institutions: Centre of Genomic Regulation (CRG)
2020: Seed round (€2m; Invivo Ventures)
Developing a novel biotherapeutic platform able to expose antigens or deliver therapeutic agents in the lung in a controlled, local and continuous manner.
FOUNDED: 2015
Medical TechnologySECTOR:
CardiovascularEXPERTISE / SPECIALITY / FOCUS:
Clinical ValidationSTAGE:
Founders: Ofir Arad, Marc Ribó
2017: Series A (€15m; Ysios, Omega funds, Innogest, Banc Sabadell)
2018: EIT Health Headstart Funding
2020: Series B (Asabys, Banc Sabadell, Innogest, Omega funds)
Developing next generation catheters to perform mechanical thrombectomies safely and efficiently.
FOUNDED: 2017
Medical TechnologySECTOR:
CardiovascularEXPERTISE / SPECIALITY / FOCUS:
Clinical ValidationSTAGE:
Founders: Judit Cubero (CEO) & Lina Badimon (CSO)
Institutions: Catalan Institute of Cardiovascular Sciences (ICCC)Spanish National Research Council (CSIC)
2017: Series A (€2.4m; Caixa Capital Risc, Healthequity)
2018: SME Instrument I & EIT Health Headstart funding (European Commission, €490k)
2019: SME Instrument II (1.9M€; European Commission)
Developing a novel in vitro diagnostic device for the early diagnosis of cardiac ischemic events to reduce the impact of the disease on patients' life.
FOUNDED: 2010
Medical TechnologySECTOR:
DiagnosticsEXPERTISE / SPECIALITY / FOCUS:
Founders: Jordi Carrera, Rafel Bru
2011: Series A (€2m, Ysios, Axis)
2013: Series B (€17m; Kurma, Indivest, Boehringer venture, Caixa Capital Risc, Ysios, axis)
2016: Series B II (€29.1m; Glide, Ysios, Kurma, Caixa Capital Risc; Boehringer, Axis, Indivest, Siemens, Philips)
2017: European Investment Bank (€20m)
2017: Exit (€154m; Qiagen)
Developing and manufacturing molecular and immunoassay diagnostics systems for decentralized clinical testing.
FOUNDED: 2011
Digital HealthSECTOR:
TelehealthEXPERTISE / SPECIALITY / FOCUS:
Class I Certified Medical Device
STAGE:
Founders:Cristian Pascual (CEO), Dr. Oscar Garcia (CMO), Roger Forcada (CTO) & Josep Carbó (CBDO)
2011: Seed Round (€1.6m, Local B.A.)
2018: Series A (€3m; Alta, Castel, Naos)
2020: Looking for series B
Developing an AI-based medical assistant that relates patient’s symptoms with possible conditions, giving recommendations on what to do next.
FOUNDED: 2013
Digital HealthSECTOR:
Mental and behavioural disorders
EXPERTISE / SPECIALITY / FOCUS:
Validation TrialsSTAGE:
Founders: Xavier Palomer (CEO) & Victor García (CTO)
2015: Seed Round (€1m; Rothenberg, Caixa Capital Risc)
2016: SME Instrument II (European Commission, €600k)
2019: Series A (€8m; Asabys, Caixa Capital Risc, CG Health Ventures, Bstartup)
Developing virtual reality-based solutions for therapeutic use in the clinical practice of mental health conditions.
FOUNDED: 2013
Digital HealthSECTOR:
Drug DevelopmentEXPERTISE / SPECIALITY / FOCUS:
Founders:Landon McKenna (CCO), Vesna Prchkovska (COO) & Paulo Rodrigues (CTO)
2014: Seed round (€160k; crowdfunding)
2017: Series A (€2.7m; Business Angels) & SME Instrument I (€50k)
2018: SME Instrument II (€300k)
2020: Series A II (€1.4m; crowdfunding)
Developing medical image processing algorithms through AI, in order to accelerate the development of new therapies for neurological diseases.
BarcelonaThe BioRegion of Catalonia
www.bioregioncatalonia.com #BioRegionCatalonia
